Nebkliq (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate and nebivolol hydrochloride, the active ingredients in Nebkliq, are a calcium channel blocker and a beta blocker presented as an oral tablet for systemic use. They treat hypertension in adult patients.

GNH USA supplies Nebkliq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebkliq combines a calcium‑channel blocker and a beta‑blocker to manage elevated blood pressure.

- Hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension. - Isolated systolic hypertension: reduces elevated systolic pressure when diastolic values are normal. - Diastolic hypertension: helps control high diastolic pressure in patients with isolated diastolic elevation.

Nebkliq may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate headache may occur. - Peripheral edema: swelling of the ankles or feet. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: general tiredness or lack of energy.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure requiring medical attention. - Bradycardia: abnormally slow heart rate. - Angioedema: swelling of face, lips, tongue, or throat. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating Nebkliq, clinicians should consider several safety measures.

- Monitor blood pressure: ensure adequate control and avoid excessive drops. - Assess cardiac function: evaluate heart rate and rhythm, especially in patients with conduction disorders. - Review concomitant medications: watch for additive hypotensive effects. - Use caution in hepatic impairment: dose adjustments may be needed. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebkliq can interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Other antihypertensive agents (e.g., ACE inhibitors, ARBs): risk of excessive blood pressure reduction. - Non‑dihydropyridine calcium‑channel blockers (e.g., verapamil, diltiazem): may cause pronounced bradycardia.

Moderate Interactions (Monitor Closely): - Diuretics: can enhance the hypotensive effect. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower drug exposure and reduce efficacy.